Drug Profile

Recombinant factor IX biobetter - UBI Pharma

Alternative Names: UB-854

Latest Information Update: 30 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator UBI Pharma
Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins; Urologics
Mechanism of Action Blood coagulation factor replacements; Factor IX replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

29 Apr 2025 Preclinical trials in Renal failure in Taiwan (Parenteral) before April 2025 (UBI Pharma pipeline, April 2025)
25 Sep 2024 Preclinical trials in Haemophilia B in Taiwan (Parenteral), prior to September 2024 (UBI Pharma pipeline, September 2024)
20 Dec 2023 Early research in Haemophilia B in Taiwan (Parenteral) (UBI Pharma pipeline, December 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com